Login
Israel-Hamas Conflict
Independence Day
Parade
Social Media
Soccer
Natural Disasters
Artificial Intelligence
Taxes
Tennis
Donald Trump
Amazon
World Cup
Floods
institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Published • loading... • Updated

Ligand’s LNHC Concludes Merger with CHRO

Summary by Pharmaceutical-technology.com
Ligand Pharmaceuticals’ subsidiary LNHC has concluded its merger with CHRO Merger Sub to form a new entity, Pelthos Therapeutics.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

2 Articles

All
Left
Center
Right
pharmaceutical-technology.compharmaceutical-technology.com

Ligand’s LNHC concludes merger with CHRO

Ligand Pharmaceuticals’ subsidiary LNHC has concluded its merger with CHRO Merger Sub to form a new entity, Pelthos Therapeutics.

Read Full Article
pelthos.compelthos.com

Pelthos Therapeutics Completes Merger with Channel Therapeutics and Closes $50.1 Million Private Placement - Pelthos Therapeutics

Open the article to view the coverage from pelthos.com

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

pelthos.com broke the news in on Wednesday, July 2, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

News
For You
SearchBlindspotLocal